

30th January, 2026

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) for Change in Senior Management Personnel of the Company

Pursuant to Regulation 30 read with Para A(7) of Part A of Schedule III and other applicable provisions of the Listing Regulations, the Board of Directors of the Company have on 30-Jan-26, based on the recommendation of the Nomination and Remuneration Committee inter alia, considered and approved appointment of **Geena Malhotra as Chief Technology Officer** of the Company categorised as Senior Management Personnel of the Company with effect from 01-Feb-26.

The disclosure in respect of the change in SMP as prescribed under Listing Regulations read with SEBI master circular no. SEBI/HO/CFD/ PoD2/CIR/P/0155 dated 11th November, 2024 is enclosed herewith as **Annexure A**.

The above is for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI
COMPANY SECRETARY

Annexure A

Sr. No.	Details of information that is required to be provided	Information of such events
1.	Name	Geena Malhotra
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Approved appointment of Geena Malhotra as Chief Technology Officer of the Company categorized as Senior Management Personnel with effect from 01-Feb-26
3.	Date of appointment/cessation (as applicable) & term of appointment	01-Feb-26 & Terms of appointment are as per the Company's Policy.
4.	Brief Profile (In case of appointment)	<p>Geena Malhotra is a seasoned pharmaceutical leader with nearly four decades of global experience spanning R&D, manufacturing, supply chain, and sustainability. Currently serving as Managing Director of Signet Excipients, she leads India's premier excipient and specialty chemical distribution enterprise, driving strategic growth, innovation partnerships, and digital transformation across pharma and biopharma segments.</p> <p>Previously, as Global CTO and President at Cipla Ltd., Geena oversaw the company's operations through various stints in R&D and manufacturing. She is recognized for fostering high-performance, inclusive organizational cultures with a focus on ESG.</p> <p>Geena has been played a key role in obtaining around 50 international patents in formulations, inhalation devices, and drug delivery systems, supporting commercial products in more than 80 countries. She has received multiple awards for scientific excellence, innovation, and leadership impact. Her experience combines scientific rigor with operational excellence, enabling organizations to deliver accessible, high-quality healthcare globally while advancing transformative technological and sustainability initiatives.</p>

	<p>Brief of her experience, achievements & education:</p> <p>Experience</p> <p>Currently serving as Managing Director at Signet Excipients since June 2024, leading strategic growth and innovation initiatives. Previously, at Cipla Ltd., held multiple senior leadership roles over three decades, including Global Chief Technology Officer & President (2018–2024), President & Global Head – Manufacturing Operations, SCM & Devices (2013–2018), Global Head – Integrated Product Development (1994–2013), and earlier R&D leadership positions (1986–1994). These roles encompassed driving global product development, operational excellence, and innovation across formulations, devices, and supply chain management.</p> <p>Awards & Recognition</p> <p>Recipient of several awards acknowledging contributions to pharmaceutical innovation and leadership. In 2024, awarded the Eminent Scientist Award for global impact on ARV affordability, respiratory innovation, and sustainability. Other recognitions include the FDD Leadership Award (2017) for outstanding achievement in formulation development and drug delivery, the Thomson Reuters Innovation Award (2012) for R&D excellence and patent leadership, and the Eminent Researcher Award (2007) from the Indian Pharmaceutical Association.</p> <p>Speaking & Industry Engagement</p> <p>An active thought leader in the pharmaceutical industry, regularly contributing to conferences and forums. Delivered keynote and technical talks, including at the IPA Sustainability Summit (2024) on water as a strategic theme for sustainable pharma operations and at the Respiratory Drug Delivery Symposium (Kerala, 2018) discussing MDIs, DPIs, and SMIs. Participated as a panellist in initiatives such as the Pharma ESG Conclave and CII Water Stewardship Initiatives.</p>
--	--

		Education Holds an Executive MBA from Washington University in St. Louis – Olin Business School (2017) and a Bachelor of Pharmacy from SNDT University, Mumbai (1985).
5.	Relationships between Directors (in case of appointment of a director)	Not Applicable